Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study
Suresh Durgam,1 Ronald P Landbloom,2 Mary Mackle,2 Xiao Wu,1 Maju Mathews,3 Henry A Nasrallah4 1Allergan Inc, Jersey City, 2Merck, Whitehouse Station, 3Forest Research Institute (now Allergan), Jersey City, NJ, 4Saint Louis University School of Medicine, St Louis, MO, USA Purpose: The primary obje...
Guardado en:
Autores principales: | Durgam S, Landbloom RP, Mackle M, Wu X, Mathews M, Nasrallah HA |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/61d88f1532d9409397d0f30c92e39abd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report
por: Okazaki K, et al.
Publicado: (2017) -
Effects of asenapine on agitation and hostility in adults with acute manic or mixed episodes associated with bipolar I disorder
por: Citrome L, et al.
Publicado: (2017) -
A STABILITY INDICATING ION-PAIR LC METHOD FOR THE DETERMINATION OF ASENAPINE IN PHARMACEUTICALS
por: KARACA,SAKINE ATILA, et al.
Publicado: (2017) -
Asenapine for bipolar disorder
por: Scheidemantel T, et al.
Publicado: (2015) -
Influence of olanzapine on serum prolactin levels and BMI in female patients with schizophrenia
por: Yang F, et al.
Publicado: (2018)